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Introduction
Refractoriness to platelet transfusions - platelet refractoriness (PR) - is defined as 
inappropriately low platelet count increments following two or more, preferably consecutive, 
transfusions(1). PR must be determined by objective data which determine platelet transfusion 
outcomes, such as the corrected count increment (CCI) and the predicted percentage recovery 
(PPR)(2).
This condition may be caused by immune and non-immune factors. Non-immune causes, 
represent the main etiology (more than 80% of cases) of platelet refractoriness and include 
splenomegaly, fever/sepsis, antibiotics or disseminated intravascular coagulation(3). Immune 
causes, occurring in less than 20% of the cases, involve alloimmunization against human 
leukocyte antigens (HLA) and, to a lesser extent, human platelet antigens (HPA) following 
exposure through transfusion, pregnancy or transplantation. Among immune causes, HLA 
antibodies are responsible for approximately 80-90% of PR cases and HPA antibodies for 
approximately 10-20% of cases, associated with HLA antibodies or not. It is important to note 
that the presence of antiplatelet antibodies does not mean PR, since in approximately 30% of 
cases, they occur in the absence of clinically detected PR(4).
The immune causes of PR can be diagnosed by laboratory tests and patients should receive 
compatible platelet transfusions(5). Testing for HPA antibodies is technically demanding and 
few laboratories offer the exam in their routine. The platelet antibody detection tests available 
include microcytotoxicity using Amos modification that detects both IgG and IgM antibodies, 
the platelet immunofluorescence test (PIFT) either by microscopy or flow cytometry 
(Capture-P®) and monoclonal antibody immobilization of platelet antigens (MAIPA)(2,6-8). The 
latter is the gold standard technique that permits the identification and quantification of platelet 
specific antibodies however this technique is very laborious and time-consuming. Thus, a fast, 
effective and low cost antibody-screening method, which could detect both HLA and HPA 
platelet antibodies is essential for the recognition and for clinical support in immune PR.
The main aim of the study was to evaluate the efficiency of the flow cytometry platelet 
immunofluorescence test (FC-PIFT) as a screening test to identify immune PR.
Background: Immune platelet refractoriness is mainly caused by human leukocyte antigen antibodies (80-
90% of cases) and, to a lesser extent, by human platelet antigen antibodies. Refractoriness can be diagnosed 
by laboratory tests and patients should receive compatible platelet transfusions. A fast, effective and low cost 
antibody-screening method which detects platelet human leukocyte/platelet antigen antibodies is essential in 
the management of immune platelet refractoriness.
Objective: The aim of this study was to evaluate the efficiency of the flow cytometry platelet immunofluorescence 
test to screen for immune platelet refractoriness.
Methods: A group of prospective hematologic patients with clinically suspected platelet refractoriness treated 
in a referral center in Campinas, SP during July 2006 and July 2011 was enrolled in this study. Platelet 
antibodies were screened using the flow cytometry platelet immunofluorescence test. Anti-human leukocyte 
antigen antibodies were detected by commercially available methods. The sensitivity, specificity and predictive 
values of the immunofluorescence test were determined taking into account that the majority of antiplatelet 
antibodies presented human leukocyte antigen specificity.
Results: Seventy-six samples from 32 female and 38 male patients with a median age of 43.5 years (range: 5-84 
years) were analyzed. The sensitivity of the test was 86.11% and specificity 75.00% with a positive predictive 
value of 75.61% and a negative predictive value of 85.71%. The accuracy of the method was 80.26%.
Conclusion: This study shows that the flow cytometry platelet immunofluorescence test has a high correlation 
with the anti-human leukocyte antigen antibodies. Despite a few limitations, the method seems to be efficient, 
fast and feasible as the initial screening for platelet antibody detection and a useful tool to crossmatch platelets 
for the transfusional support of patients with immune platelet refractoriness.
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Table 1 - Clinical data of patients enrolled in the study
Table 2 - Distribution of the results of the flow cytometry platelet 
immunofluorescence test (FC-PIFT) versus anti-human leukocyte antigen 
antibody (PRA) 
Patients
Disorder
Oncologic
(N = 58 - 83%)
Non-oncologic
(N = 12 - 17%)
Myeloproliferative Lymphoproliferative
Gender - n (%) 7 (58)
Male 20 (34) 11 (19) 5 (42)
Female 19 (33) 8 (14)
Age (years) 28.5
Median 49.7 40.5 7-79
Range 15-84 5-60 0.013
FC-PIFT PRA
n % n %
Positive 39 51 36 47
Negative 35 46 40 53
Inconclusive 02 03
Methods
A group of hematologic patients with clinically suspected 
PR treated at the hospital complex of the Universidade Estadual 
de Campinas during the period July 2006 to July 2011 was 
prospectively enrolled in this study. Serum samples were 
collected before transfusion for direct platelet antibody screening 
and samples were then stored at -20°C until processing. 
Platelet antibodies were screened by the FC-PIFT. Sera 
from 24 regular male blood donors with no history of previous 
transfusions were analyzed and a negative fluorescence standard 
curve was defined. Pooled platelets from two O blood group 
male donors with no history of previous sensitization were buffer 
washed and re-suspended in 0.1% phosphate buffered saline (PBS)/
ethylenediaminetetraacetic acid (EDTA) (final concentration 100,000 
platelets/mL) and then incubated with patient serum (5 mL) for 30 
minutes at 37°C. Negative and positive controls were added to each 
test batch. After three consecutive washes, cells were incubated for 
50 minutes with fluorescein isothiocyanate (FITC) goat anti-human 
immunoglobulin G [AffiniPure F(ab’) Fragment Goat Anti-Human 2 
IgG, Fc Fragment Specific - Jackson Immuno Research – Baltimore, 
USA] at 1:50 dilution. Samples were read after a second buffer wash 
in a FACScalibur flow cytometer (Becton Dickinson, San Jose, CA, 
USA) using the CellQuestH software (Becton Dickinson). For data 
acquisition and analysis, 10,000 events were analyzed. The test was 
considered positive if the median fluorescence (MF) obtained was 
greater than or equal to two standard deviations (SD) above the 
negative MF control and inconclusive if MF was between one and 
two SD above the negative MF control.
Anti-human leukocyte antigen antibody analysis
The detection of anti-HLA antibodies (PRA) was 
determined by commercially available methods: enzyme-linked 
immunosorbent assay (ELISA - LAT® One Lambda Inc, Canoga 
Park, CA, USA) and Luminex technology (LabScreen® and 
LabSingle Antigen® One Lambda Inc, Canoga Park, CA, USA) 
according to the manufacturer´s instructions.
Flow cytometry platelet immunofluorescence test 
versus anti-human leukocyte antigen antibody analysis 
The results of FC-PIFT and PRA obtained from the samples 
collected were compared. The sensitivity and specificity as well 
as predictive values of FC-PIFT were determined taking into 
account that the majority of antiplatelet antibodies present HLA 
specificity.
Statistical analysis
The R software version 2.13.1 (2011-07-08) was used for 
statistical analysis. The Fisher exact test was applied for count 
data with the level of significance set at 0.5% (p-value ≤ 0.05). 
Since the great majority of antibodies involved in PR present 
HLA specificity(3), PRA was used as a reference test to calculate 
sensitivity, specificity, and positive and negative predictive 
values of FC-PIFT(9,10).
Results
Population characteristics
This prospective study analyzed 76 blood samples from 32 
female and 38 male patients with a median age 43.5 years (range: 
5-84 years). The group characteristics are described in Table 1. Of 
the patients studied, 55.7% (n = 39) presented myeloproliferative 
oncologic disorders and 27.1% (n = 19) lymphoproliferative 
disorders. Non-oncologic disorders were detected in 17.1% (n 
= 12) (Bernard Soulier Syndrome, Glanzmann’s thrombasthenia 
and aplastic anemia). 
Correlation Flow cytometry platelet 
immunofluorescence test versus anti-human leukocyte 
antigen antibody analysis
There were correlations between positive FC-PIFT and 
positive PRA in 38.15% (n = 29) and negative FC-PIFT and 
negative PRA in 39.47% (n = 30) of the samples. On the other 
hand, the FC-PIFT was positive when the PRA was negative in 
13.16% (n = 10) and the FC-PIFT was negative when the PRA 
was positive in 6.58% (n = 5) of the cases. Finally the FC-PIFT 
was inconclusive when the PRA was positive in 2.6% of the total 
samples (n = 2). Data are shown in Table 2. 
Flow cytometry platelet immunofluorescence test - 
sensitivity and specificity
The sensitivity FC-PIFT was 86.11% and the specificity was 
75.00% with a positive predictive value of 75.61% and a negative 
predictive value of 85.71%. The accuracy of the method was 
80.26%. Data are shown in Table 3.
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Discussion
The present study demonstrates that FC-PIFT is an 
interesting tool to identify patients with immune PR. The test 
is fast, relatively simple and allows the selection of compatible 
platelet donors by crossmatching to support thrombocytopenic 
patients or those with platelet dysfunction bleeding.
The identification of antibodies against antigens present on 
the platelet surface strongly suggests immune PR, nevertheless 
the majority of PR cases have non-immune causes. When 
immune factors are present, the identification of the antibodies 
linked to the platelets, as well as the availability of compatible 
platelet components, may significantly enhance the response to 
platelet transfusion and improve patient outcome. 
There is a significant association between platelet transfusion 
failure and patient survival; this increases the clinical impact of 
platelet refractoriness(11). Providing an adequate post-transfusion 
platelet count increment in refractory patients is not an easy task 
and so transfusion of compatible platelets is crucial, particularly 
in immune PR(12). HLA is the most frequent cause of immune 
PR and finding multiple HLA-compatible related donors for one 
individual is very difficult. 
Successful transfusion of patients with platelet-refractory 
thrombocytopenia is extremely important(13,14). However, several 
potential donors are needed to sustain HLA platelet matched 
transfusion programs considering not only HLA diversity but also 
the transfusional demand of these patients. Pool size calculations 
may provide essential data for a rational planning of platelet 
transfusion support programs and help guide different institutions 
that aim to build a platelet donor registry. Feasibility and costs 
should be taken into account when considering the donor pool 
size required(15).
The use of HLA platelet matching is not the only approach 
to manage alloimmune platelet transfusion refractoriness. 
Crossmatching and support with antigen negative platelet units 
allow rapid selection of donors, mainly for those patients with 
uncommon HLA types to whom it might be virtually impossible 
to find HLA-compatible donors(16-18). Recently, the use of the 
HLAMatchmaker algorithm has been reported as an emerging 
concept for the management of refractory patients(19). The 
combination of matching compatible antigens and the application 
of mismatch acceptability determined by serum screening for 
HLA antibodies has offered an effective approach for HLA-based 
platelet transfusion support of refractory patients.
This study showed that the FC-PIFT has a high correlation 
with PRA, and also demonstrated good sensitivity, accuracy and 
a high positive predictive value. A larger number of patients 
analyzed could improve the statistics of the study, reducing the 
confidence interval found (Table 3). However, due to the low 
frequency of hematological patients with suspected PR, even 
with cooperative studies, the ideal number of patients enrolled 
probably could not be achieved. FC-PIFT does not discriminate 
the specificity of antiplatelet antibodies (anti-HLA antibodies or 
anti-HPA antibodies) and some limitations of the method should 
be discussed. The frequency of positive FC-PIFT with negative 
PRA (13%) suggests the presence of HPA antibodies (in agreement 
with the literature 10-20%). Moreover, the great polymorphic 
diversity of the HLA system imposes another limitation for FC-
PIFT; the use of pooled platelets from two random donors may 
not ensure the ideal range of antigens. However, the use of more 
platelet donors could cause a ‘dilution’ of the HLA antigens. 
Conclusions
Even with limitations, the FC-PIFT seems to be efficient, fast 
and feasible as an initial screening to detect platelet antibodies and 
a useful tool to crossmatch platelets for the transfusional support 
of patients with refractoriness. The use of additional techniques 
that identify anti-HPA antibodies, such as MAIPA, is essential for 
the appropriate clinical management of these cases. 
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